Topic: Glp 3

A licensed therapist from Portland, Oregon, warns about the "mental health industrial complex," where normal human emotions are increasingly pathologized and medicalized through social media influence. The discussion also covers the rise of GLP-3 peptides, marketed as the "Wolverine peptide," and the potential side effects of over-medicating personality traits.

A discussion on peptides and GLP-1 weight loss drugs explores a University of Colorado study suggesting these drugs may reduce brain inflammation and improve attention. The hosts joke that taking GLP-1s might lead people to vote Democrat. They plan a "deep dive" into the peptide subculture for a future show, noting the high number of "peptide nuts" among their audience.

Eli Lilly is developing Rettatrutide, a new obesity drug that targets three hormones and reportedly leads to a 28% weight loss, comparable to bariatric surgery. While medical professionals call it "game-changing," critics point to side effects like "joy loss," where patients lose interest in food, sex, and other pleasures. The drug is expected to be submitted for FDA approval by the end of the year.

Users of GLP-1 weight loss drugs are reporting significant side effects, including hair loss, muscle atrophy, and "ozempic face." The hair treatment industry is reportedly seeing a billion-dollar opportunity as a result of these complications. The segment warns that the aesthetic benefits of rapid weight loss are often offset by these systemic health issues.

Research into GLP-1 weight loss medications like Ozempic suggests potential side effects including decreased libido and sexual dysfunction. The hosts discuss how these drugs affect dopamine reward pathways in the brain, potentially contributing to the declining U.S. birth rate. The segment explores the irony of medications intended to make users more attractive simultaneously reducing their desire for intimacy.

A study from the University of Pennsylvania used AI to analyze 400,000 Reddit posts to identify underreported side effects of GLP-1 drugs like Ozempic and Wegovy. The research found patterns of menstrual irregularities and body temperature regulation issues that were not prominent in clinical trials. Researchers suggest this AI framework could be used to monitor the safety of other rapidly growing medications.

A supercut by Milk Bar TV highlights Candace Owens' repeated claims over two years that she is "inching closer" to solving the assassination of Charlie Kirk. The segment also touches on the growing infighting among conservative media figures like Megyn Kelly and Mark Levin. Additionally, there is speculation that GLP-1 drugs like Ozempic may eventually be used to treat digital addictions.

A 2015 study from the National Library of Medicine suggests that chewing sugarless gum can increase GLP-1 concentrations and satiety, potentially serving as an economical weight-loss tool similar to Ozempic. The hosts jokingly propose a "No Agenda Death-Bound Gum" brand.

New medical research suggests that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may reduce the risk of erectile dysfunction. The hosts view this as the final stage of a massive marketing campaign for the drugs, which have already been linked to reduced risks for heart attacks, alcoholism, and smoking.

British pop star Robbie Williams reportedly developed scurvy, a 17th-century pirate disease caused by vitamin C deficiency, as a side effect of using Ozempic. The discussion touches on the aggressive marketing of GLP-1 drugs and the various side effects being reported as the market share for weight-loss medications expands.

Oprah Winfrey appeared on CBS with Dr. Anya Yastroboff to discuss obesity as a chronic disease rather than a failure of willpower. Winfrey shared her personal experience of regaining weight after briefly stopping GLP-1 medications, concluding that she must remain on the drugs for life. The discussion frames obesity as a biological condition that causes overeating.

Research published in the British Medical Journal warns that patients who stop taking GLP-1 drugs like Ozempic or Wegovy may face rapid weight gain and increased risks of diabetes and heart disease. Doctors emphasize that these medications are long-term commitments rather than quick fixes.

Listener feedback highlighted a decline in gym attendance attributed to the rising use of GLP-1 weight-loss drugs. Medical professionals in the community also noted a shift from SSRIs to more potent antipsychotic cocktails among patients. Meanwhile, entrepreneurs within the "No Agenda" stable are launching new ventures in strength training and job search services, utilizing the show's network for promotion.

A massive consumer trend toward protein-enriched products is being driven by the popularity of GLP-1 weight-loss drugs like Ozempic. Because users on these drugs eat fewer meals, they are seeking "protein-maxing" options like Starbucks protein lattes and Kroger's protein-focused product lines.

A new study suggests that GLP-1 weight loss medications like Ozempic and Wegovy may increase testosterone levels and prevent erectile dysfunction in men. The hosts speculate that the media is slow-walking this information until the current marketing cycle for weight loss reaches its peak. They suggest this "positive" side effect will eventually be used as a primary selling point for the drugs.

CNN featured oncologist Dr. Elizabeth Komen discussing how obesity and alcohol consumption are primary modifiable risk factors for cancer. The hosts deconstruct the segment as a "native ad" for GLP-1 drugs like Ozempic, suggesting the medical establishment is pivoting toward pharmaceutical solutions for weight-related cancer risks. They advise avoiding processed foods with barcodes as a simpler preventative measure.

A discussion regarding new studies published on PubMed and by the NIH suggests that GLP-1 drugs like Wegovy and Ozempic may improve erectile dysfunction. The hosts characterize this as a calculated marketing pivot to get the drugs into a wider population following the decline of COVID-19 vaccine sales.

Endocrinologist Dr. Rekha Kumar discusses a new oral version of GLP-1 weight-loss drugs that does not require refrigeration or injections. Clinical trials show weight loss results comparable to injectables like Ozempic and Mounjaro, with a 16-pound average loss over 40 weeks. The hosts express skepticism about the long-term safety of these "pills for junk food" and advise listeners to stay away from the medication.

In Austin, Texas, a growing trend of "concierge injection specialists" allows residents to receive Botox and GLP-1 weight-loss drugs at hair salons or private homes. The local culture remains politically polarized, with some residents expressing extreme views regarding figures like Elon Musk. Despite the city's reputation as a tech hub, social circles often remain insulated, with service providers acting as confidants for those with dissenting political opinions.

Listeners clarified the role of a "nurse injector," a term used for medical professionals certified to administer Botox and fillers. The "aesthetic nurse injector" featured in recent media was likely an expert in cosmetic procedures rather than a general health expert. This context explains her warnings against "black market" GLP-1 weight loss drugs, as many aesthetic offices now offer semaglutide as a side service.